Food Effects on the Relative Bioavailability of a Risedronate 20 mg Delayed-Release [DR] Tablet and to Compare the 20 mg DR Tablet to 35 mg DR and 35 mg Immediate-Release Tablets.
Phase of Trial: Phase I
Latest Information Update: 11 Oct 2011
At a glance
- Drugs Risedronic acid (Primary)
- Indications Male osteoporosis; Postmenopausal osteoporosis
- Focus Pharmacokinetics
- Sponsors Procter & Gamble
- 24 Mar 2010 Actual patient number (94) added, Warner Chilcott added as trial sponsor and affiliate as reported by ClinicalTrials.gov.
- 15 Dec 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 14 Aug 2008 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.